En route to a potential FDA approval next month, Pacira Pharmaceuticals ($PCRX) reports data from previous trials of its lead drug Exparel for postsurgical pain. In patients who had surgery to enlarge their breasts and took the drug, there were no signs of ill effects in healing or breast appearance 13 months and two years after their surgeries. The data were presented on Sept. 24 at the annual American Society of Plastic Surgeons meeting in Denver. The FDA is expected to complete its review of the drug for postsurgical pain and decide whether to give it a market green light by Oct. 28. Exparel consists of the approved drug bupivacaine and is encased in liposome particles that enable the active ingredient to be released gradually. Release